4 citations
,
February 2024 in “The Journal of Urology” This study reports that adding androgen deprivation therapy to salvage radiation therapy for patients with non-metastatic biochemical recurrence of prostate cancer after radical prostatectomy improves progression-free survival, particularly in those with higher post-prostatectomy PSA levels.
35 citations
,
January 2012 in “The Journal of Sexual Medicine” This review examines various androgen deprivation therapy methods for advanced prostate cancer, highlighting benefits and potential cardiovascular and sexual adverse effects, but reports no new clinical results.
7 citations
,
August 2019 in “Bioorganic & medicinal chemistry” This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.
34 citations
,
July 2020 in “Frontiers in immunology” This mini-review discusses the role of androgens, specifically testosterone and dihydrotestosterone, in the pathogenesis of autoimmune liver diseases and reports no new results.
May 2024 in “Scientific Reports” In this study, researchers examined androgen receptor activity in the adult mouse brain and found specific expression in key brain areas, which could inform understanding of cognitive side effects in humans undergoing androgen deprivation therapy for prostate cancer.